CHDS5
MCID: CRN214
MIFTS: 22

Coronary Heart Disease 5 (CHDS5) malady

Categories: Genetic diseases

Aliases & Classifications for Coronary Heart Disease 5

Aliases & Descriptions for Coronary Heart Disease 5:

Name: Coronary Heart Disease 5 54 66 29
Coronary Heart Disease, Susceptibility to, 5 13 69
Coronary Artery Disease Early-Onset 66
Chds5 66

Classifications:



External Ids:

OMIM 54 608901
MedGen 40 C1837173
MeSH 42 D003324

Summaries for Coronary Heart Disease 5

UniProtKB/Swiss-Prot : 66 Coronary heart disease 5: A multifactorial disease characterized by an imbalance between myocardial functional requirements and the capacity of the coronary vessels to supply sufficient blood flow. Decreased capacity of the coronary vessels is often associated with thickening and loss of elasticity of the coronary arteries.

MalaCards based summary : Coronary Heart Disease 5, also known as coronary heart disease, susceptibility to, 5, is related to heart disease. An important gene associated with Coronary Heart Disease 5 is KALRN (Kalirin RhoGEF Kinase). The drugs Simvastatin and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include heart.

Description from OMIM: 608901

Related Diseases for Coronary Heart Disease 5

Diseases in the Coronary Heart Disease 6 family:

Coronary Heart Disease 2 Coronary Heart Disease 5
Coronary Heart Disease 7 Coronary Heart Disease 9
Coronary Heart Disease 8 Coronary Heart Disease 4
Coronary Heart Disease 3

Diseases related to Coronary Heart Disease 5 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 heart disease 9.7

Symptoms & Phenotypes for Coronary Heart Disease 5

Clinical features from OMIM:

608901

Drugs & Therapeutics for Coronary Heart Disease 5

Drugs for Coronary Heart Disease 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1381)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 3,Phase 1,Phase 2 79902-63-9 54454
2
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
5
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1 274693-27-5 9871419
6
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1 88150-42-9 2162
7
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-61-7 60961
8
Dipyridamole Approved Phase 4,Phase 3,Phase 2,Phase 1 58-32-2 3108
9
Regadenoson Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 313348-27-5 219024
10
Ezetimibe Approved Phase 4,Phase 3 163222-33-1 150311
11
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-78-2 2244
12
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
13
Warfarin Approved Phase 4,Phase 3,Phase 2 81-81-2 6691 54678486
14
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 72956-09-3 2585
15
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 772 46507594
16
Nicorandil Approved Phase 4,Phase 2 65141-46-0 47528
17
Ticlopidine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 55142-85-3 5472
18
Ramipril Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 87333-19-5 5362129
19
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2 144701-48-4 65999
20
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
21
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 37350-58-6, 51384-51-1 4171
22
Udenafil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 268203-93-6 6918523
23
Bisoprolol Approved Phase 4,Phase 3,Phase 2 66722-44-9 2405
24
Candesartan Approved Phase 4,Phase 3,Phase 2 139481-59-7 2541
25
Diltiazem Approved Phase 4,Phase 3,Phase 2,Phase 1 42399-41-7 39186
26
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2 13422-51-0 11953898 5460373 44475014
27
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 51-43-4 5816
28
Dobutamine Approved Phase 4,Phase 3,Phase 2,Phase 1 34368-04-2 36811
29
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
30
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
31
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 58-93-5 3639
32
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137862-53-4 60846
33
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
34
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54-31-9 3440
35
Metolazone Approved Phase 4,Phase 2,Phase 1 17560-51-9 4170
36
Abciximab Approved Phase 4,Phase 3,Phase 2 143653-53-6
37
Bivalirudin Approved, Investigational Phase 4,Phase 3 128270-60-0 16129704
38
Digoxin Approved Phase 4,Phase 3,Phase 2 20830-75-5 30322 2724385
39
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
40
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
41
Nitroglycerin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-63-0 4510
42
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Early Phase 1 58-18-4 6010
43
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 58-22-0 6013
44
Irbesartan Approved, Investigational Phase 4,Phase 2 138402-11-6 3749
45
Desflurane Approved Phase 4 57041-67-5 42113
46
Isoflurane Approved, Vet_approved Phase 4,Phase 2,Phase 3 26675-46-7 3763
47
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 2078-54-8 4943
48
Remifentanil Approved Phase 4,Phase 3,Phase 2 132875-61-7 60815
49
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
50
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients Unknown status NCT02001883 Phase 4
2 Test of Long-Term Safety and Efficacy of Sirolimus-Permanent-Polymer Eluting Stent (Cypher)- and Sirolimus-Polymer-free Eluting Stents (PPS/PFS) Assessed by Optical Coherence Tomography Unknown status NCT01260558 Phase 4
3 GISSOC II: Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Coronary Occlusions Unknown status NCT00220558 Phase 4
4 Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4
5 Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing Unknown status NCT01456364 Phase 4
6 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4
7 Lexiscan(TM) Rb-82 Myocardial Perfusion PET: A Comparison With Dipyridamole Stress Unknown status NCT00808314 Phase 4
8 Atorvastatin Plus Ezetimibe on Coronary Plaque Progression Unknown status NCT01086020 Phase 4
9 Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent Unknown status NCT01233453 Phase 4
10 Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP Unknown status NCT00584350 Phase 4
11 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4
12 Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol Unknown status NCT01425164 Phase 4
13 Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4
14 Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing Unknown status NCT00698607 Phase 4
15 Telmisartan Versus Ramipril After Acute Coronary Syndrome Unknown status NCT00702936 Phase 4
16 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4
17 Comparison of Efficacy of Ivabradine Versus Metoprolol Unknown status NCT01755663 Phase 4
18 Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image Unknown status NCT01769482 Phase 4
19 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4
20 Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD Unknown status NCT02008786 Phase 4
21 Sternal Closure With Biologic Bone Cement in Patients Undergoing Coronary Artery Bypass Grafting (CABG) Unknown status NCT01261858 Phase 4
22 Intracoronary Administration of Levosimendan in Cardiac Surgery Patients Unknown status NCT01500785 Phase 4
23 Spinal Cord Stimulation (SCS) in Refractory Angina Unknown status NCT00121654 Phase 4
24 Vitamin D and Inflammatory Cytokine Levels After Acute Myocardial Infraction (MI) Unknown status NCT01115842 Phase 4
25 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4
26 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4
27 Customized Choice of Oral P2Y12 Receptor Blocker Unknown status NCT01477775 Phase 4
28 Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome Unknown status NCT01951001 Phase 4
29 Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment Unknown status NCT01761786 Phase 4
30 A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure Unknown status NCT02135835 Phase 4
31 Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients Unknown status NCT01101698 Phase 4
32 Outcome and Safety of Intermittent Dobutamine Infusion at a Day-Care Center in Advanced Heart Failure Patients Unknown status NCT01930734 Phase 4
33 Fractional Flow Reserve Versus Angiography Randomization for Graft Optimization Trial Unknown status NCT02477371 Phase 4
34 LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients Unknown status NCT02077257 Phase 4
35 Colchicine in ST-elevation Myocardial Infarction Unknown status NCT01936285 Phase 4
36 Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines Unknown status NCT00885651 Phase 4
37 Ivabradine in Hemodialysed Patients With Increased Heart Rate Unknown status NCT01364077 Phase 4
38 A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions Unknown status NCT00825773 Phase 4
39 Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy Unknown status NCT02166060 Phase 4
40 Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome Unknown status NCT02341729 Phase 4
41 Hormones Inflammation and Thrombosis Unknown status NCT01875185 Phase 4
42 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4
43 Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial Unknown status NCT00937092 Phase 4
44 A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients Unknown status NCT00690521 Phase 4
45 Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4
46 Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI Unknown status NCT01158846 Phase 4
47 Effect of Conditioning on Myocardial Damage in STEMI Unknown status NCT02158468 Phase 4
48 Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction Unknown status NCT02046044 Phase 4
49 Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics. Unknown status NCT02087332 Phase 4
50 Study of Effects of Sildenafil on Patients With Fontan Heart Circulation Unknown status NCT01815502 Phase 4

Search NIH Clinical Center for Coronary Heart Disease 5

Genetic Tests for Coronary Heart Disease 5

Genetic tests related to Coronary Heart Disease 5:

id Genetic test Affiliating Genes
1 Coronary Heart Disease 5 29

Anatomical Context for Coronary Heart Disease 5

MalaCards organs/tissues related to Coronary Heart Disease 5:

39
Heart

Publications for Coronary Heart Disease 5

Variations for Coronary Heart Disease 5

ClinVar genetic disease variations for Coronary Heart Disease 5:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 KALRN NC_000003.12: g.124055231T> G single nucleotide variant risk factor rs9289231 GRCh37 Chromosome 3, 123774078: 123774078

Expression for Coronary Heart Disease 5

Search GEO for disease gene expression data for Coronary Heart Disease 5.

Pathways for Coronary Heart Disease 5

GO Terms for Coronary Heart Disease 5

Sources for Coronary Heart Disease 5

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....